Is meningococcal B vaccine available free in other Australian states?

Currently, MenB vaccine is funded through the National Immunisation Program only for Aboriginal and Torres Strait Islander infants and for children with specific medical conditions that increase their risk. Tasmania's new program is separate — a state-funded scheme for all infants aged 6 weeks to 2 years in Tasmania from 1 July 2026. If you are in another state, MenB vaccine is available through general practice but at private prescription cost. Ask your GP or practice nurse about current pricing and the vaccination schedule.

Tasmania extends free MenB vaccine to all infants from 1 July

Q: Which meningococcal vaccines does my child need?

There are several different groups of meningococcal bacteria. The MenACWY vaccine (which covers four groups: A, C, W, and Y) is on the National Immunisation Program at 12 months and again at age 14–16. The MenB vaccine (covering the B strain, which is the most common cause of invasive meningococcal disease in Australian infants) is NOT currently on the NIP for most children — Tasmania's new program is specifically addressing this gap. Your GP or maternal and child health nurse can clarify which vaccines your child has received and which are still due.

What just happened

From 1 July 2026, Tasmania has become the first Australian state to fund meningococcal B vaccination for all infants — not just those in specific high-risk categories.

The program, backed by a $4 million state government investment, covers infants aged 6 weeks to 2 years, delivered through general practices and select council clinics. Catch-up vaccination is available for children born from 1 July 2025 onwards. Previously, the MenB vaccine was available in Tasmania only via private prescription — at a cost of approximately $100–$150 per dose, with multiple doses required in the schedule.

Dr Prashanth Reddy Gangapuram, commenting on the announcement, named what the program actually removes: “It might be rare, but it can cause life-threatening consequences in children if it’s not immunised against” — and that the financial barrier had been the obstacle for many families.

State Health Minister Bridget Archer was direct: “Our $4 million investment removes that barrier, ensuring every Tasmanian infant can receive this protection at no cost.”

To put the disease context in numbers: 39 meningococcal cases have been reported nationally so far in 2026, with 12 of those in children under five. The B strain is consistently the most common cause of invasive meningococcal disease in Australian infants.

The both-and

Why is this only in Tasmania?

The MenACWY vaccine — which covers meningococcal groups A, C, W, and Y — has been on the National Immunisation Program at 12 months and again at ages 14–16 for some years. The MenB vaccine covers a different strain and is not on the NIP for most Australian infants. The NIP does fund it for Aboriginal and Torres Strait Islander infants and for children with specific medical risk factors — but for the general infant population, it has remained a private-prescription expense.

The reason MenB is not universally NIP-funded is partly economic modelling: the disease is rare at the population level, and cost-effectiveness thresholds that inform NIP decisions have not been met in all analyses. That calculation feels different when it is your child, which is why the out-of-pocket cost has always functioned as a quiet rationing mechanism — parents who could afford the vaccine bought it, those who couldn’t did not.

Tasmania’s program bypasses that by funding it at state level. It is a policy decision that says: the cost-effectiveness threshold is not the only consideration. Equity of access is also a consideration. Whether other states follow is the question to watch.

What the speed of meningococcal disease means clinically

Meningococcal disease can be fatal within 24 hours of the first symptom. In infants, the classic signs — neck stiffness, photophobia, non-blanching rash — often appear late or are absent in the early hours. Early presentations in young children can look like a non-specific febrile illness, which is why the disease is so difficult to catch in time and why prevention is so much more effective than diagnosis.

The MenB vaccine series cannot be started before 6 weeks of age, and the schedule requires multiple doses over several months to achieve full coverage. This means the window of vulnerability in very young infants is not completely closed by vaccination — but the program substantially reduces the period of unprotected exposure in the first two years, when risk is highest.

2 cents

If you have an infant in Tasmania, this program is now active. Your general practice can advise on the schedule and check your child’s immunisation history through the Australian Immunisation Register.

If you are outside Tasmania and you want MenB vaccination for your infant, it remains available through general practice at private prescription cost. Whether that cost is reasonable for your family is a conversation to have with your GP — who can walk you through the schedule, the timing relative to other vaccines, and the current out-of-pocket price at your practice.

For parents with infants who have completed their first year without MenB vaccination, it is worth asking about catch-up timing. The disease does not respect the administrative boundary of a vaccine program’s start date.

Verdict: yes — practical, life-saving, and a model other states should examine.

Sources cited

RACGP newsGP — Free meningococcal B vaccines for Tassie infants. 2 July 2026. https://www1.racgp.org.au/newsgp/clinical/free-meningococcal-b-vaccines-for-tassie-infants
Australian Government — National Immunisation Program Schedule. https://www.health.gov.au/topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule